Hanmi Pharmaceutical Co., Ltd. 128940

MegazoneCloud (CEO Doug Yeum), a leading AI and cloud company, is undertaking the development of 'Hanmi Q-Agent,' an AI agent that automates Hanmi Pharmaceutical's quality assurance (QA) operations, based on its enterprise AI OS 'AIR Studio.'

The licensing deal marks a diversification of Roche’s obesity pipeline as it seeks entry into the lucrative market.

For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.

Hanmi Pharm announced today that it has entered into an exclusive licensing agreement with Genentech, a member of the Roche Group, for the development, manufacturing, and commercialization of Hanmi's novel metabolic treatment candidate, HM17321 (UCN2), for obesity and associated conditions such as type 2 diabetes and cardiovascular diseases, worldwide. The agreement excludes South Korea.

SAN DIEGO and TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced the closing of the plan of arrangement (announced on November 19, 2025 and February 24, 2026) pursuant to which HS North America Ltd. (the “Purchaser”), a wholly owned s

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global GLP-1 Receptor Agonist Market size & share revenue was valued at approximately USD 28.7 Billion in 2025 and is expected to reach USD 34.2 Billion in 2026 and is expected to reach around USD 95.3 Billion by 2035, at a CAGR of 12.1% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Novo Nordisk A/S, Eli Lill

Eli Lilly's recent GLP-2 deal with Hanmi Pharm is another step in the drugmaker’s quest to grow its GLP franchise beyond weight loss and deepen its push into gastrointestinal disease.

Eli Lilly (NYSE:LLY) has agreed to acquire three vaccine and infectious disease companies, Curevo, LimmaTech Biologics, and Vaccine Company, in deals totaling nearly US$4b. The acquisitions expand Eli Lilly's reach beyond its core obesity and diabetes franchises into vaccines and infectious diseases. Alongside these acquisitions, Eli Lilly has recently entered partnerships in genetic and RNA based therapies with groups including Ascidian Therapeutics, Hanmi Pharm, and Haisco Pharmaceutical...

Eli Lilly (NYSE:LLY) is pushing beyond its obesity drug franchise with plans to acquire three vaccine focused biotech companies. The company has also entered new collaborations in genetic and RNA based therapies with partners including Ascidian Therapeutics, Hanmi Pharm, and Haisco Pharmaceutical Group. These moves come alongside broader offerings on LillyDirect, signaling a wider repositioning of its product pipeline. Eli Lilly, trading at $1,131.42, has seen very large share price gains...

Eli Lilly and Co. announced separate licensing and research agreements with South Korea-based Hanmi Pharm and China-based Haisco Pharmaceutical Group, expanding its access to new drug candidates and discovery programs. The deals come as investors also evaluate positive Phase 3...

Hanmi will receive $75m upfront and may earn up to $1.185bn in milestone payments for development and approvals.

Hanmi Pharm. Co., Ltd. ("Hanmi") today announced that they have entered into a license agreement for the development, manufacturing and commercialization of Hanmi's biologic drug candidate sonefpeglutide (LAPSGLP-2 analog) with Eli Lilly and Company ("Lilly").

SAN DIEGO and TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) announced today that closing of the previously announced arrangement (the “Arrangement”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) and HS North America Ltd., a wholly owned subsidiary of Hanmi (“Hanmi Purchaser” and together with Hanmi, the “Hanmi Purchasers”), has been further delayed as certain Korean regulatory approvals pertaining to the Arrangement remain in

Cardiovascular and Respiratory medicines to be supplied in Malaysia and the PhilippinesShin Hae-gon (right), Head of Overseas Sales at Hanmi Pharmaceutical, and Andreas Daugaard Jørgensen (left), Managing Director, Organon Asia Pacific Cluster, met at Organon’s Malaysia office to discuss the expansion of Hanmi’s combination therapies into the Southeast Asian market. SEOUL, South Korea, May 21, 2026 (GLOBE NEWSWIRE) -- Hanmi Pharmaceutical announced that it has signed a supply agreement with glob

SAN DIEGO and TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update. “Our TUSCANY clinical trial of tuspetinib in combination with venetoclax (V

Shareholders approve acquisition of Aptose by Hanmi Pharmaceutical in “Go Private” transaction TUS+VEN+AZA triplet frontline therapy continues to demonstrate favorable safety and high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutations SAN DIEGO and TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-base

Shareholders are Recommended to Vote “FOR” the Aptose BiosciencesProposed Plan of Arrangement with Hanmi Pharmaceutical Shareholders are Reminded of Voting Deadline for Upcoming Special Meeting SAN DIEGO and TORONTO, March 23, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) is pleased to announce that Glass, Lewis & Co. (“Glass Lewis”), a leading independent proxy advisory firm, has recommended that Aptose shareholders (the “Shareholders”) vote

Opportunities in the rolvedon market include rising demand for patient-friendly oncology drugs, focus on improving treatment adherence, and growing investments in biologics. Expansion of outpatient cancer care and increased cancer prevalence enhance market growth. Asia-Pacific leads in growth potential, while tariffs influence costs.Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Rolvedon Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to Research